Risk Factors and elsewhere in this Form 10-K. All statements, other than statements of historical facts, included herein that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements, including statements regarding:  The Companys ability to increase, and methods for increasing, BioGlue and preserved tissue market penetration;  The Companys continued use of human tissue implant data;  The expected benefits of surgical adhesives and sealants;  The Companys plans to apply for further federal funding for the development of BioFoam;  The anticipated competitive advantages and potential impact on revenues, of SynerGraft;  Expected increases in grant revenues;  Expectations regarding, and possible increases in the cost and retention of, future insurance coverage;  Current intentions not to pay cash dividends on our common stock;  Current intentions to retain future earnings for capital requirements;  Expectations regarding the use of net operating loss carryforwards,  Expected decreases in revenues from the distribution of orthopaedic tissue;  Expectations regarding the impact of CryoValve SG pulmonary heart valve on cost of preservation services as a percentage of preservation services revenues;  Expectations regarding capital expenditures;  Expected usage of SynerGraft technology;  Expected timing regarding availability of CryoValve SG;  Commercialization plans regarding ProPatch;  Potential BioGlue product line extensions;  The potential benefits of products licensed from Trophic Solutions;  Information regarding the expected SynerGraft post-clearance study;  The ability of BioGlue to minimize post-operative pain following hernia operations;  The expected outcome of lawsuits filed against the Company;  The Companys estimated future liability for existing product liability lawsuits and for product liability claims incurred but not yet reported;  The Companys competitive position, including the impact of price increases;  The receipt of governmental grants for BioFoam development;  Future increases in research and development expenses;  Competitive advantages offered by the Companys patents, trade secrets, trademarks, and technology licensing rights;  Expected impact of adoption of new accounting pronouncements;  Expected seasonality trends;  Anticipated impact of changes in interest rates;  The ability to expand the Companys service and product offerings;  Those issues most likely to impact the Companys future financial performance and cash flows;  The anticipated impact of the Companys strategic plans and its ability to implement them;  The adequacy of the Companys financial resources; and  Other statements regarding future plans and strategies, anticipated events, or trends. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments as well as other factors it believes are 30 appropriate under the circumstances. However, whether actual results and developments will conform with the Companys expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from the Companys expectations, including the risk factors discussed in Item 1.A of this Form 10-K and other factors, many of which are beyond the control of CryoLife. Consequently, all of the forward-looking statements made in this Form 10-K are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. The Company assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events, or otherwise. Item 1B. Unresolved Staff Comments. The Company has no unresolved written comments received from the staff of the Securities and Exchange Commission regarding its periodic or current reports under the Securities Exchange Act of 1934 not less than 180 days before December 31, 2007 (the end of the fiscal year to which this Form 10-K relates). 